Glyn Edwards, Chief Executive Officer
Mr Glyn Edwards was appointed to the Board of Directors as Chief Executive Officer in April 2012. Mr Edwards has a wealth of experience garnered from a thirty-year career in the life sciences industry, during which time he has held a number of senior executive and business development roles. Prior to joining Summit, he was interim Chief Executive Officer of the UK trade body the BioIndustry Association (BIA) and Chief Executive Officer at Antisoma plc for 13 years, and Vice President of Business Development at Therapeutic Antibodies Ltd. Mr Edwards holds a BSc in Biochemistry from Bristol University and an MSc in Economics from the London Business School.
Erik Ostrowski, Chief Financial Officer
Mr Erik Ostrowski was appointed as our Chief Financial Officer in June 2014. Prior to joining Summit Mr Ostrowski served as Vice President of Finance at Organogenesis Inc., a biotechnology company, from 2010 to 2014. Prior to that, Mr Ostrowski worked in investment banking, most recently as a Director with Leerink Partners LLC. Mr Ostrowski began his career as an accountant with Coopers & Lybrand. Mr Ostrowski received a Bachelors of Science in Accounting and Economics from Babson College and an MBA from the University of Chicago Booth School of Business.
David Roblin, Chief Operating Officer and President of R&D
Dr David Roblin joined as our Chief Operating Officer and President of Research and Development in a part-time capacity beginning in April 2017 and becomes full-time in June 2017. Dr Roblin has been acting as a research and development adviser to us since 2014. Dr Roblin has served as the Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London from 2014 to 2017. Prior to that, Dr Roblin was Head of Research, Site Director and Chief Medical Officer for Europe R&D at Pfizer Inc. from 2008 to 2011 and was Head of Therapy Area for Anti-infectives at Bayer AG from 1997 to 1999. After Dr Roblin left Pfizer Inc., he was Chief Medical Officer to a number of biotechnology companies including Creabilis SA where he held that role from 2011 until 2014. Dr Roblin has a degree in biochemistry from University College London and later qualified in medicine from St George’s Hospital. He is a Fellow of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine. He is an honorary Professor of Medicine at Swansea University and Professor of Translational Medicine at St George’s. He is also a member of the board of directors of MedCity and Destiny Pharma Ltd. Before entering the life sciences industry, Dr Roblin practised medicine for five years.